Souvik Sarkar1, Zhen Jiang, Donna M Evon, Abdus S Wahed, Jay H Hoofnagle. 1. Liver Disease Branch, Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, United States.
Abstract
BACKGROUND & AIMS: Fatigue is the most frequent and often debilitating symptom of chronic hepatitis C. It is unclear whether successful therapy of hepatitis C leads to its clinical improvement. In the Virahep-C study, patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a and ribavirin for up to 48 weeks while undergoing assessment of viral kinetics and clinical symptoms. METHODS: Fatigue measurements were conducted, before, during and after therapy, as 'presence' (yes/no) and 'severity' (visual analog scale: 0-100mm). The clinical, histologic, and virologic features that correlated with the presence and degree of fatigue were assessed focusing upon changes associated with sustained virological response (SVR). RESULTS: At baseline, 52% (n=401) of participants reported having fatigue, which was more common in women than men (59% vs. 48%, p=0.02) and slightly more severe (30 vs. 22 mm, p=0.056). Fatigue was frequent and worse in cirrhotics versus those with lesser fibrosis (66% vs. 49%; 34 vs. 24 mm). Fatigue did not correlate with other parameters. The proportion of patients and median fatigue scores increased on treatment (52-78%; 25-40 mm, p<0.0001) with higher fatigue noted amongst those who ultimately achieved SVR (p<0.0001). On achieving SVR, there was a significant decrease in both frequency and severity of fatigue compared to their baseline (53-33%; 27-13 mm, both p<0.0001). CONCLUSIONS: Fatigue is common in patients with chronic hepatitis C but is poorly associated with biochemical parameters. Sustained response is accompanied by substantial improvement of fatigue. Published by Elsevier B.V.
BACKGROUND & AIMS:Fatigue is the most frequent and often debilitating symptom of chronic hepatitis C. It is unclear whether successful therapy of hepatitis C leads to its clinical improvement. In the Virahep-C study, patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a and ribavirin for up to 48 weeks while undergoing assessment of viral kinetics and clinical symptoms. METHODS:Fatigue measurements were conducted, before, during and after therapy, as 'presence' (yes/no) and 'severity' (visual analog scale: 0-100mm). The clinical, histologic, and virologic features that correlated with the presence and degree of fatigue were assessed focusing upon changes associated with sustained virological response (SVR). RESULTS: At baseline, 52% (n=401) of participants reported having fatigue, which was more common in women than men (59% vs. 48%, p=0.02) and slightly more severe (30 vs. 22 mm, p=0.056). Fatigue was frequent and worse in cirrhotics versus those with lesser fibrosis (66% vs. 49%; 34 vs. 24 mm). Fatigue did not correlate with other parameters. The proportion of patients and median fatigue scores increased on treatment (52-78%; 25-40 mm, p<0.0001) with higher fatigue noted amongst those who ultimately achieved SVR (p<0.0001). On achieving SVR, there was a significant decrease in both frequency and severity of fatigue compared to their baseline (53-33%; 27-13 mm, both p<0.0001). CONCLUSIONS:Fatigue is common in patients with chronic hepatitis C but is poorly associated with biochemical parameters. Sustained response is accompanied by substantial improvement of fatigue. Published by Elsevier B.V.
Authors: H Van Vlierberghe; M Adler; B Bastens; I Colle; J Delwaide; J Henrion; Y Horsmans; P Michielsen; P Golstein; J-P Mulkay; W Van Steenbergen; P Yap; F Nevens; A M Denys; J-P Brasseur Journal: Acta Gastroenterol Belg Date: 2010 Jan-Mar Impact factor: 1.316
Authors: Gordon Broderick; Jim Fuite; Andrea Kreitz; Suzanne D Vernon; Nancy Klimas; Mary Ann Fletcher Journal: Brain Behav Immun Date: 2010-05-04 Impact factor: 7.217
Authors: Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch Journal: J Hepatol Date: 2006-11-27 Impact factor: 25.083
Authors: Donna M Evon; Darmendra Ramcharran; Steven H Belle; Norah A Terrault; Robert J Fontana; Michael W Fried Journal: Am J Gastroenterol Date: 2009-09-29 Impact factor: 10.864
Authors: Norah A Terrault; Kelly Im; Ross Boylan; Peter Bacchetti; David E Kleiner; Robert J Fontana; Jay H Hoofnagle; Steven H Belle Journal: Clin Gastroenterol Hepatol Date: 2008-08-19 Impact factor: 11.382
Authors: Matthias Majer; Leonie A M Welberg; Lucile Capuron; Giuseppe Pagnoni; Charles L Raison; Andrew H Miller Journal: Brain Behav Immun Date: 2008-02-06 Impact factor: 7.217
Authors: Souvik Sarkar; Denise A Esserman; Melissa Skanderson; Forrest L Levin; Amy C Justice; Joseph K Lim Journal: J Hepatol Date: 2016-04-27 Impact factor: 25.083
Authors: Montserrat Masip; Laura Tuneu; Neus Pagès; Xavier Torras; Adolfo Gallego; Josep Maria Guardiola; María José Faus; Maria Antònia Mangues Journal: Int J Clin Pharm Date: 2015-08-13
Authors: Donna M Evon; Abdus S Wahed; Geoffrey Johnson; Mandana Khalili; Mauricio Lisker-Melman; Robert J Fontana; Souvik Sarkar; Bryce B Reeve; Jay H Hoofnagle Journal: Dig Dis Sci Date: 2016-01-30 Impact factor: 3.199